Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.

International heart journal - 31 Mar 2023

Yanase Tomonobu, Hatano Masaru, Bujo Chie, Tsuji Masaki, Ishida Junichi, Amiya Eisuke, Okamoto Koh, Ando Masahiko, Shimada Shogo, Kinoshita Osamu, Fukushi Shuetsu, Yamada Souichi, Ono Minoru, Komuro Issei

Abstract excerpt

Currently available anti-cytomegalovirus (CMV) agents are sometimes poorly tolerated, owing to their side effects. Letermovir is a novel anti-CMV drug that is only approved for CMV prophylaxis in hematopoietic stem cell transplant recipients, with fewer side effects. We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus Infections

Share to Ganciclovir

Share to Heart Transplantation

Share to Mutation

Share to Viremia

Source

Identifiers

PMID: 36682771
DOI: 10.1536/ihj.22-496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.PMID 36682771Read ↗

Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).Semantic proximity Read ↗

Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.Semantic proximity Read ↗

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.Semantic proximity Read ↗

Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.Semantic proximity Read ↗

High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.Semantic proximity Read ↗

The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.Semantic proximity Read ↗

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experienceSemantic proximity Read ↗

Approach to drug-resistant cytomegalovirus in transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.